Hutchison China MediTech: The market sales of FRUZAQLA®, sold by Takeda, increased by 26% to $366.2 million.

LightningPacketLoss · 2026-03-06T19:00:26+00:00

Hutchison China MediTech (Hutchmed) announced its 2025 performance, with total revenue of $549 million, down 13%. Core profit was $457 million, mainly derived from the sale of non-core businesses. Revenue from oncology products declined, while sales of FRUZAQLA® increased by 26%. The ATTC technology platform has entered clinical trials, and collaborations with multinational pharmaceutical companies are anticipated.

LightningPacketLoss

2026-03-06 19:00:26

Abstract generation in progress

Recently, Hutchison MediPharma announced its full-year 2025 performance and latest business developments, with core business profits and the sale of non-core businesses generating a net income of $457 million.

The announcement shows total revenue of $549 million, a 13% decrease compared to 2024. Shareholder profit attributable to equity holders was $457 million. Among them, revenue from oncology products was $285 million (2024: $363 million), mainly affected by several factors, including declining sales of Evotaz®, Sutent®, and Votrient® in the Chinese market.

The financial review section mentions that the market sales of FRUZAQLA® increased by 26% to $366 million, thanks to successful product launch and expanded insurance coverage. The market sales of Evotaz® reached $100 million. Additionally, Votrient® received approval for a third lung cancer indication in China, triggering an $11 million milestone payment from AstraZeneca.

In the management discussion and analysis section, it is noted that the ATTC technology platform has entered clinical trials, with multiple candidate drugs actively progressing, and potential collaboration opportunities with multinational pharmaceutical companies to develop ATTC candidate drugs are anticipated. In the overall business segments, the oncology/immunology division and other businesses performed differently; the oncology/immunology segment continues to focus on new drug development and market expansion, while other businesses maintained stable revenue.

(Hutchison MediPharma Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes